Linda Thunell has worked in the pharmaceutical industry for more than 23 years. Linda was the CEO and founding partner of Sofus Regulatory Affairs AB (“Sofus”), a consultancy company within the fields of Drug Development, Regulatory Affairs, and Quality Assurance, which she founded in 2002. Sofus Regulatory Affairs was acquired by Xendo Holding B.V. in 2017 and today is the leading Nordic consultancy company within Regulatory Affairs consisting of more than 60 people. Following ProPharma Group’s acquisition of Xendo and Sofus, Linda Will remain CEO, Sofus Regulatory AB.
Before founding Sofus, Linda was Head of Regulatory Affairs at Galderma Nordic, a pharmaceutical company specializing in dermatology. While there, Linda established the Nordic department for Regulatory Affairs, Pharmacovigilance, and Quality Assurance and was responsible for pricing and reimbursement applications, as well as promotional materials. Linda has also served as the Head of Regulatory Affairs at Meda, a Swedish specialty pharma company, where she established the department for Regulatory Affairs, Pharmacovigilance, and Quality Assurance. Linda served and as an Officer at the Swedish MPA, and as a Project Secretary for the Nordic Council on Medicines. Linda has also acted as QPPV and RP and earned her MSc in Toxicology from the Karolinska Institute in Stockholm, Sweden, and her BSc in Pharmaceutical Bioscience from Uppsala University in Uppsala, Sweden.
